

References

Abdel-aziz F, Habib M, Mohammed MK.(2003): Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. *Hepatology*; 32 (1) :111-5.

Abdel-Hamid M.(2010): Efficacy and clinical response to Reifron Retard® in patients with chronic hepatitis C in Egypt. *Presented at BITs 1st World Congress of Virus and Infections (Busan-South Korea) July 2010, 2(1): 121-129.*

Abdel-Wahab MF, Zakaria Sand Kamel M. (1994): High seroprevalence of hepatitis C infection among risk groups in Egypt. *American Journal of Tropical Medicine and Hygiene*, 51 (5),p 563-567.

Abdul Bari, Saeed Akhtar, Mohammad H.(2001): Hepatitis C antibody prevalence in blood donors in Egypt. *Tropical Medicine and International Health*: volume 6 no 9 p. 132-738.

Aceijas C and Rhodes T. (2007): Global estimates of HCV infection among injecting drug user; *Int J Drug Policy*. 18(5): 338–340.

Adinolfi LE, Giordano MG, Andreana A, Tripodi MF, Utili R,et al; (2001): Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. *Br J Haematol*; 113:590-597.

Afdhal N, Flamm S, Imperial JC, et al. (2001):Analyses of 40 KDA peginterferon alfa-2a in combination with ribavirin, mycophenolate mofetil, amantadine or amantadine plus ribavirin .multicenter, efficacy and safety studies [Abstract]. *Hepatology*;34(Suppl.):243-249.

Afdhal N, McHutchison J, Brown R, et al. (2008): Thrombocytopenia associated with chronic liver disease. *J Hepatol*;48: 1000-1007.

Akhtar, T. Moatter, S.I.Azem, et al.(2002): Prevalence and risk factors for intra familial transmission of HCV in Karachi, Pakistan; *Journal of Viral Hepatitis*; 9:309-314.

Akhtar S and Moatter T. (2004): Intra-household clustering of HCV infection in Karachi, Pakistan. *Trans R Soc Trop Med Hyg*, 98 : 535-9.

Aktipi KM, Ravaglia S, Ceroni M. (2007): Severe recurrent myelitis in patients with hepatitis C virus infection. *Neurology*;68: 468–469.

Alaa AT , Motaz H , Ahmad E , Maged E , Emad AR.(2010): Efficacy and safety of Hansenula-derived PEG interferon alpha-2a 160 ug , Ribavirin and Amantadine combination in treatment of chronic HCV-genotype 4 Egyptian patients. *Presented at 17th International Meeting on HCV and Related Viruses(Yokohama-Japan)September 2010 ,3(1):312-319.*

Alberti A (1998): Recent advantages in understanding HCV. International Conference on Hepatitis C . *Monte Carlo*, 9-10 January, 1998.

Alric L, Fort M, Izopet J, Vinel JP, Charlet JP, Selves J, et al. (1997) : Genes of the major histocompatibility complex class 11 influence the outcome of hepatitis C virus infection. *Gastroenterology*; 113:1675-1681.

Altaf A, et al. (2004): Determinants of therapeutic injection overuse among communities in Sindh, Pakistan. *J Ayub Med Coll Abbottabad* 16:35–38.

Alter MJ. (1992) : New kit on the block: Evaluation of second-generation assays for detection of antibody to the hepatitis C virus. *Hepatology*; 15:350-358.

Alter MJ. (1993): the detection, transmission and outcome of hepatitis C virus infection. *Inject Agents Dis*; 2:155-166.

Alter MJ.(1997): The epidemiology of acute and chronic hepatitis C.*Clin Liver Dis*;1(3):559-568.

Alter MJ, Kruszon-Moran D, Nainan QV, McQuillan GM, et al; (1999): The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. *N Engl J Med*; 341:556-562.

Alter MJ, Kuhnert WL, Finelli L (2003): Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. *MMWR Recomm Rep*; 52:1.

Alter MJ, Tokars J, Arduino M, et al., (2004): Nosocomial infections associated with dialysis. In. Glen C. Mayhall, ed. Hospital Epidemiology and Infection Control 3rd ed New York: Lippincott Williams & Wilkins:1150-1.

Alter MJ. (2007): Epidemiology of hepatitis C virus infection. *World J Gastroenterol*; 13(17):2436-41.

Anouk Dev, Vijaya Sundararajan and William Sievert (2004): Ethnic and cultural determinants influence risk assessment for hepatitis C acquisition; *Journal of Gastroenterology and Hepatology*; 19; 792-798.

Antonelli A, Ferri C, Pampana A, et al. (2004): Thyroid disorders in chronic hepatitis C. *Am J Med* 117: 10-13.

Arafa N, Hoseiny ME, Rekacewicz C, et al.(2005). Changing pattern of HCV spread in rural areas of Egypt. *J Hepatol*, 43 :418-24.

Arase Y, Ikeda K, Murashima N, et al. (1998): Glomerulonephritis in autopsy cases with hepatitis C virus infection. *Intern Med*;37:836-40.

Aref S, Sleem T, El Menshawy N, et al. (2009): Antiplatelet antibodies contribute to thrombocytopenia associated with chronic hepatitis C virus infection. *Hematology*;14: 277-281.

Arthur RR, Hassan NF, Abdallah MY, El Sharkawy MS, Saad MD, (1997): Hepatitis C antibody prevalence in blood donors in different governorates in Egypt. *Trans. R. Soc. Trop. Med. Hyg.* 91:271-274.

Askarian M, Mirzaei K, McLaws ML (2006): Attitudes, beliefs, and infection control practices of Iranian dentists associated with HIV-positive patients. *Am J Infect Control* 34:530–533.

Askarian M, Mirzaei K, Cookson B (2007): Knowledge, attitudes, and practice of Iranian dentists with regard to HIV-related disease. *Infect Control Hosp Epidemiol* 28:83–87.

Ayas NT, Barger LK, Cade BE, Hashimoto OM, Rosner B, et al. (2006): Extended work duration and risk of self-reported percutaneous injuries in interns. *JAMA*; 296: 1055.

Bacon BR et al; (2011): for the HCV RESPOND-2 investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. *N Engl J Med* Mar 31; 364:1207.

Barrera JM, Francis B, Ercilfa G, Neffes M, Achord O, Darner J et al. (1995): Improved detection of anti-HCV in post-transfusion hepatitis by a third generation ELISA. *Vox Sang*; 68: 15.

Bartenschlager R, Lohmann V. (2000): Replication of hepatitis C virus. *J Gen Virol*; 81(Pt7): 1631-48.

Bassily S, Hyams KC, Fouad RA, Samaan MD, Hibbs RG (1995): A high risk of hepatitis C infection among Egyptian blood donors: the role of parenteral drug abuse. *Am J Trop Med Hyg* 52:503–505.

Batts KP, Ludwig J. (1995): Chronic hepatitis. An update on terminology and reporting. *Am J Surg Pathol*;19:1409-1417.

Beaulieu PL. (2009); Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection. *Expert Opin Ther Pat.* 19(2):145–164.

Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. (1961): An inventory for measuring depression. *Arch Gen Psychiatry*;4:561-571.

Bedossa P, Poynard T. (1996) : An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *Hepatology* ;24:289-293.

Beeck A, Dubuisson J. (2003): "Topology of hepatitis C virus envelope glycoproteins". *Rev. Med. Viral.*;13(4):-233-41.

Bellentani S, Pozzato G, Saccoccio G, et al. (1999): Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. *Gut* ;44:874-880.

Berenguer M, Ferrell L, Watson J, et al. (2000): HCV-related fibrosis progression following liver transplantation: increase in recent years.*J Hepatol*;32:673-684.

Berg T, von Wagner M, Nasser S, et al. (2006): Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. *Gastroenterology*;130:1086-1097.

Bino T, Madar Z, Gertler A, et al. (1982): The kidney is the main site of interferon degradation. *J Interferon Res*;2:301-308.

Blajchman MA, Bull SB, Feinman SV, (1995): Post-transfusion hepatitis: impact of non-A, flon-B hepatitis surrogate tests. *Lancet* ;345:21-25.

Bocci V, Pacini A, Muscettola M, et al. (1981): Renal filtration, absorption and catabolism of human alpha interferon. *J Interferon Res*;1:347-352.

Boguszewska-Chachulska AM, Krawczyk M, Najda A, et al. (2006): Searching for a new anti-HCV therapy: synthesis and properties of tropolone derivatives. *Biochem Biophys Res Commun.*;341(2): 641–647.

Bordin G, Ballare M, Zigrossi P, et al. (1995):A laboratory and thrombokinetik study of HCV-associated thrombocytopenia: a direct role of HCV in bone marrow exhaustion? *Clin Exp Rheumatol*;Suppl 13: S39-43.

Borowski P, Lang M, Haag A, Baier A. (2007): Tropolone and its derivatives as inhibitors of the helicase activity of hepatitis C virus nucleotide triphosphatase/helicase. *Antivir Chem Chemother.*;18(2):103–109.

Braun WF, McCauley J., (1998): Post-transplant outpatient case. In: Nonnan DJ, Suki WN, eds. *Primer on Transplantation. New Jersey: American Society of Transplant Physicians*; 229-44.

Brillanti S, Foli M, Gaiani S (1993): Persistent hepatitis C viraemic without liver disease. *Lancet*; 341:46.

Bronowicki JP, Venard V, Botte C, et al. (1997): Patient to patient transmission of HCV during colonoscopy. *N Engl J Med*;337:237-40.

Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, et al. (1989): Prevalence of antibodies to hepatitis C virus in panish patients with hepatocellular carcinoma. *Lancet*; 2:1004.

Bruix J, Sherman M. (2005): Management of hepatocellular carcinoma. *Hepatology*;42:1208-1236.

Bruno S, Stroffolini T, Colombo M, et al. (2007): Sustained virological response to interferon-alpha is associated with improved outcome in HCV- related cirrhosis: a retrospective study. *Hepatology*;45:579-587

Bukh J, Miller R, Purcell R. (1995): Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes. *Semin Liver Dis*; 15:41.

Busch MP, Wilber JC, Johnson PJ, Tobler L, Evans CS. (1992): Impact of specimen handling and storage on detection of hepatitis C virus RNA. *Transfusion*;32:4205.

Busch MP, Lee SR. (1997): Yield of HCV EIA 3.0 vs EIA 2.0 in screening US blood donors (abstract). *Transfuson*; 37(Suppl):111S.

Buti M, Sanchez-Avila F, Lurie Y, et al. (2002): Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. *Hepatology*; 35:930-936.

Calès P, Oberti F, Michalak S, et al. (2005): A novel panel of blood markers to assess the degree of liver fibrosis. *Hepatology*; 42: 1373-1381.

Cacoub P, Sbai A, Hausfater P, et al. (1998): Central nervous system involvement in hepatitis C virus infection. *Gastroenterol Clin Biol*; 22: 631–633.

Canry-Cantilena C, Van Raden M, Gibble J, Melpalder J, Shakil AO, Viladomiu L, et al. (1996): Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. *N Engl J Med*; 334:1691.

Carrozzo M, Gandolfo S, carbone M, et al. (1996): Hepatitis C virus infection in Italian patients with oral lichen planus: a prospective case-control study. *J Oral Pathol Med*;25: 527-33.

Carta MG, Hardoy MC, Garofalo A, et al. (2007): Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy. *Clin Pract Epidemiol Ment Health*;3: 22.

Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, et al.(2005): Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology* 28:343-350.

Cemy A, Chisari FV(1999): Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. *Hepatology* 30:595-601.

Center for disease control (CDC) and prevention. (1998): Recommendations for prevention and control of HCV infection and HCV-related chronic disease. *MMWR*,47 (no.RR-19): 1-33.

Chao TC, Chen CY, Yang YH, et al. (2001): Chronic hepatitis C virus infection associated with primary warm-type autoimmune hemolytic anemia. *J Clin Gastroenterol*;33: 232-233.

Chau TN, Lee KC, Yao H, et al.,(2004): SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. *Hepatol*,39 : 302-10.

Cheng G, Montero A, Gastaminza P, et al (2008); A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. *Proc Natl Acad Sci U S A*. 105(8):3088–3093.

Cheruvattath R, Rosati MJ, Gautam M, et al. (2007): Pegylated interferon and ribavirin failures: is retreatment an option? *Dig Dis Sci*;52:732-736.

Cheung RC and Keeffe EB.(1997): HGV: clinical relevance and responsiveness to IFN. *Am J Gastroenterol*,92 : 1957-58.

Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, (1989): Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science*; 244:359.

Christina F, Mostafa K Thomas Strickland, et al., (2000): The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt; *Lancet*. march 11, 2000. Vo1355 : 887-891.

Conte D, Fraquelli M, Prati D, et al., (2000): Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. *Hepatology*;31:751-5.

Cornberg M, Hadem J, Herrmann E, et al. (2006): Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open label pilot study. *J Hepatol*;44:291-301.

Corrao G, Arico S. (1998): Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. *Hepatology*;27:914-919.

Craxi A, Lo Iacono O. (2001): Amantadine for chronic hepatitis C: a magic bullet or yet another dead duck. *J Hepatol*;35:527-530.

Crockett SD, Kaltenbach T, Keeffe EB. (2006): Do we still need a liver biopsy? Are the serum fibrosis tests ready for prime time? *Clin Liver Dis*;10:513-534, viii.

Czaja AJ, Freese DK. (2002): Diagnosis and treatment of autoimmune hepatitis. *Hepatology*;36:479-497.

Damani NN, (1997): Manual of Infection Control Procedures. *Hepatology*. Jan; 28(1):248-53.

Darwish NM, Abbas MO, Abdelfattah FM, Darwish MA (1992): Hepatitis C virus infection in blood donors in Egypt. *J Egypt Public Health Assoc*, 67:223–236.

Darwish MA, et al. (1993): Risk factors associated with a high seroprevalence of hepatitis C virus infection in Egyptian blood donors. *Am J Trop Med Hyg*, 49:440–447.

Darwish NM, Abbas MO, Hady SI, Mohammed TA (1995): Study of the high prevalence of HCV in Egypt. *J Egypt Public Health Assoc* 70:397–414.

Darwish MA, Faris E and Clemens ID, (1996): High seroprevalence of hepatitis A, B, C and E viruses in residents in an Egyptian village in the Nile delta: a pilot study. *Am J Trop Med Hyg*; 54: 554-58.

Davis GL and Lau JY. (1997): Factors predictive of a beneficial response to therapy of hepatitis C. *Hepatology*; 26(Suppl 1):122S.

Davis GL. (2002): Monitoring of viral levels during therapy of hepatitis C. *Hepatology*; 36:S145.

Davis GL, Wong JB, McHutchison JG, et al. (2003): Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. *Hepatology*;38: 645-652

De Almeida AJ, Campos-de-Magalhaes M, Okawa MY, et al.(2004):HepatitisC virus-associated thrombocytopenia: a controlled prospective, virological study. *Ann Hematol*;83: 434-440.

Deelder AM, Miller RL, De Jonge, Krijger FW (1990):Detection of schistosome antigen in mummies. *Lancet*; 335: 724-2 .

De la Serna- Higuera C, Bárcena-Marugán R, Sanz-de Villalobos E.(1999): Hemolytic anemia secondary to alpha interferon treatment in a patient with chronic C hepatitis. *J Clin Gastroenterol*;28: 358-9.

Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ .(1994): Classification of chronic hepatitis: diagnosis, grading and staging. *Hepatology*; 19:1513-1520.

Di Bisceglie AM, McHutchison J, Rice CM. (2002): New therapeutic strategies for hepatitis C. *Hepatology*;35:224-231.

Dienstag JL, McHutchison JG. (2006): American Gastroenterological Association technical review on the management of hepatitis C. *Gastroenterology*.;130:231–64.

Duberg AS, Nordström M, Törner A, (2005): Non-Hodgkin's lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. *Hepatology* 41: 652-659.

Durantel D, Alotte C, Zoulim F. (2007); Glucosidase inhibitors as antiviral agents for hepatitis B and C. *Curr Opin Investig Drugs*. 8(2):125–129.

Dusheiko G, Smith M and Scheuer PJ (1990): Hepatitis C virus transmitted by human bite (Letter). *Lancet*; 336:503-504.

Dusheiko G, Schmilovitz-Weiss H, Brown O, McOmish F, et al. (1994): Hepatitis C virus genotypes: An investigation of type-specific differences in geographic origin and disease. *Hepatology*; 19:13.

Dussol B, Berthezene P, Brunet P ,et al., (1995): Hepatitis C virus infection among chronic dialysis patients in the south of france: A collaborative study. *Amer J Kidney Dis* ;25: 399-404.

Dustin LB., Rice C.M (2007): Flying under the radar: the immunobiology of Hepatitis C. *Annu Rev Immunol*; 25:71-99.

Dymock BW. (2001): Emerging therapies for hepatitis C virus infection. *Emerg Drugs*;6:13-42.

EASL International Consensus Conference on Hepatitis C (1999): Consensus Statement. *Journal of Hepatology*, 1999,31 :3-8.

Eassa S, Eissa M,Sharaf SM, Ibrahim MH, Hassanein OM (2007): Prevalence of hepatitis C virus infection and evaluation of a health education program in el-ghar village in zagazig, egypt. *J Egypt Public Health Assoc* 82:379–404.

Einav S, Elazar M, Danieli T, Glenn JS. (2004); A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates HCV RNA replication. *J Virol.* 78(20):11288–11295.

Einav S, Gerber D, Bryson PD, et al (2008); Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. *Nat Biotechnol.* 26(9):1019–1027.

Elazar M, Liu M, McKenna SA, et al. (2009): The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. *Gastroenterology.* 137(5):1827–1835.

El Gohary A , et al.(1995): High prevalence of hepatitis C virus among urban and rural population groups in Egypt. *Acta Trop* 59:155–161.

EL-Raziky MS, EL-Hawary M, EL-Koofy N,et al.(2004):HCV infection in Egyptian children: single centre experience. *J Viral Hepat*, 11 :471-6.

EI-Sadawy M, Ragab H, EL-Toukly H, et al (2004): HCV infection at Sharkia Governorate ,Egypt: seroprevalence and associated risk factors. *J Egypt Soc Parasitol*,34(1 suppl) :367-84.

El-Sayed HF, Abaza SM, Mehanna S. (1997): The prevalence of hepatitis B and C infections among immigrants to a newly reclaimed area endemic for *Schistosoma mansoni* in Sinai, Egypt. *Acta Trop*; 68: 229-37.

El-Zanaty F, Way A (2009): Egypt Demographic and Health Survey 2008. Egyptian: Ministry of Health (El-Zanaty and Associates and Macro International, Cairo), p 431.

England K, Pembrey L, Tovo PA, Newell ML. (2005): Excluding hepatitis C virus (HCV)infection by serology in young infants of HCV-infected mothers. *Acta Paediatr*; 94:444.

Esteban JI, Genesca J, Alter HJ.(1992): Hepatitis C Molecular biology, pathogenesis,epidemiology, clinical features and prevention. In: Boyer JL, Ockner RK eds.*Progress in Liver diseases*. Vo110. Philadelphia: WB. Saunders:253-282.

Esteban JI, Gomez J, Martell M, et al. (1996):Transmission of HCV by a Cardiac surgeon. *N Engl J Med*,334: 555-60.

Farci P, Alter HJ, Shimoda A, Govindarajan S, et al. (1996): Hepatitis C virus associated fulminant hepatic failure. *N Engl J Med*,;335(9):631-634.

Farci P, Shimoda A, Mong D, et al., (1996): Prevention of HCV infection in chimpanzees by hyperimmune serum against the HVRI of the envelope 2 protein. *Proc Nat Acad Sci USA*, 93: 15394-99.

Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, et al. (2000): The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. *Science*; 288:339.

Farghaly AG, Barakat RM, (1993): Prevalence, impact and risk factors of hepatitis C infection. *J Egypt Public Health Assoc* 68:63–79.

Fargion S, Piperno A, Cappellini MD et al. (1992): Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association.*Hepatology*; 16: 1322-26.

Fattovich G, Giustina G and Degos F (1997)a: Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 348 patients. *Gastroenterology*; 112:463-472.

Fattovich G, Giustina G and Degos F(1997)b: Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. *J Hepatol*; 27: 201-205.

Ferenci P, Fried MW, Shiffman ML, et al. (2005): Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. *J Hepatol* ;43:425-433.

Fernandéz A. (2006): An unusual case of autoimmune hemolytic anemia in treatment naïve hepatitis C virus infection. *Hematology*;11: 385–387.

Ferri C, Sebastiani M, Guigliolo D, et al. (2004): Mixed cryoglobulinaemia: demographic, clinical, and serologic features and survival in 231 patients. *Semin Arthritis Rheum*;33: 355-374.

Fisman ON, Harris AD, Rubin M, Sarock GS, (2007): Fatigue increases the risk af injury from sharp devices in medical trainees: results from a case cross over study. *Infect Control Hosp Epidemiol*; 28:10.

Fontana RJ, Israel J, LeClair P, Banner BF, et al. 2000): Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. *Hepatology* ;1:730-736.

Forns X, Martinez-Bauer E, Feliu A, et al.(2004): Nosocomial transmission of HCV in the liver unit of a tertiary care center. *Hepatol*,41: 115-122.

Forton OM, Thomas HC, Murphy CA, Allsop JM, et al. (2002): Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease.*Hepatology*; 35:433.

Forton DM, Taylor-Robinson SD, Thomas HC. (2003): Cerebral dysfunction in chronic hepatitis C infection. *J Viral Hepat*;10: 81-86.

Foy E, Li K, Wang C, et al. (2003); Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. *Science*. 300(5622): 1145–1148.

Foy E, Li K, Sumpter R Jr, et al. (2005); Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. *Proc Natl Acad Sci U S A*. 102(8):2986–2991.

Frank C, Mohamed MK, Strickland GT, et al. (2000): The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. *Lancet*;355(9207):887-91.

Frese M, Schwarzle V, Barth K, et al. (2002): Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. *Hepatology*;35:694-703.

Fried MW, Shindo M, Fong TL, et al., (1992): Absence of hepatitis C viral RNA from saliva and semen of patients with chronic hepatitis C. *Gastroenterology*. APR;102(4 PT 1):1306-8.

Fried MW, Shiffman ML, Reddy KR, et al. (2002): Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med*;347:975-982.

Gamal E , Hoda EN , (2010): Efficacy and safety of Hansenula-derived PEG interferon alpha-2a 160 ug plus Ribavirin in chronic HCV-genotype 4 Egyptian patients. *Presented at 1st Annual meeting of "Mediterranean Association For Study of Liver"(Naple, Italy)June 2010; 4(1).*

García-Suárez J, Burgaleta C, Hernanz N, et al. (2000): HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant alpha2b-interferon therapy. *Br J Haematol*;110: 98-103.

Garfein RS, Vlahov D, Galai N, et al., (2004): Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency viruses. *Am J Public Health*; 86: 655-661.

Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, Chisari FV (2008); Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. *J Virol*. 82(5):2120–2129.

Gerlach JT, Diepolder HM, Jung MC, Gruener NH, et al. (1999): Recurrence of hepatitis C virus after loss of virus-specific CD4 T-cell response in acute hepatitis C. *Gastroenterology*; 117:933.

Ghany MG, Strader DB, Thomas DL, Seeff LB. (2009): Diagnosis, management, and treatment of hepatitis C:an update. *Hepatology*; 49:1335.

Giacchino R, Tasso L, TimitilliA, Castagnola E, et al. (1998): Vertical transmission of hepatitis C virus infection: usefulness of viremia detection in HIV seronegative hepatitis C virus-seropositive mothers. *J Pediatr*; 132:167.

Giordano TP, Henderson L, Landgren O,(2007): non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. *JAMA*;297: 2010-2017.

Girou E, Chevaliez S, Challine D, et al; (2008): Determinant roles of environmental contamination and non compliance with standard precautions in the risk of hepatitis C virus transmission in a hemodialysis unit. *Clin Infect Dis*; 47(5): 627-33.

Glue P. (1999): The clinical pharmacology of ribavirin. *Semin Liver Dis*; 19 Suppl 1:17-24.

Glue P, Fang JW, Rouzier-Panis R, et al. (2000): Pegylated interferon- alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. *Clin Pharmacol Ther*;68:556-567.

Gonzalez-Peralta RP, Qian K, She VS, Davis GL, et al. (1996): Clinical implications of viral quasispecies in chronic hepatitis C. *J Med Virol*;49:242.

Gorrin G, Friesenhahrl M, Un P, Sanders M, et al. (2003): Performance evaluation of the VERSANT HCV RNA qualitative assay by using transcription-mediated amplification. *J Clin Microbiol*; 41:310.

Grakoui A, Shoukry NH, Woollard DJ, Han JH, et al (2003): HCV persistence and immune evasion in the absence of memory T cell help. *Science*; 302:659.

Grant,A and Neuberger J (1999): Guidelines on the use of liver biopsy in clinical practice. *Gut*;45(Supp14):1-11.

Grant PR, Kitchen A, Barbara JA, Hewitt P, Sims CM, et al, (2000): Effects of handling and storage of blood on the stability of hepatitis C virus RNA: Implications for NAT testing in transfusion practice. *Vox Sang*; 78:137.

Gremion C., Cemy A (2005):Hepatitis C virus and the immune system: a Concise review. *Rev Med Virol*;15(4):235-68.

Gretch OR, Lee W, Corey L. (1992): Use of aminotransferase, hepatitis C antibody, and hepatitis C polymerase chain reaction RNA assays to establish the diagnosis of hepatitis C virus infection. *J Clin Microbiol*;30:2145.

Gretch OR. (1997): Diagnostic tests for hepatitis C. *Hepatology*; 26:43S.

Gruner N.H.(2000): Association of hepatitis C virus-specific CD8⁺ T cells with viral clearance in acute hepatitis C . *J Infect DIS*; 181(5):1528-36.

Guechot J, Loria A, Serfaty L, et al. (1995): Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C. Effect of alpha interferon therapy. *J Hepatol*; 22: 22-6.

Guechot J, Laudat A, Loria A, et al. (1996): Diagnostic accuracy of Hyaluronan and type III procollagen aminoterminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. *Clin Chem*; 42: 558-63.

Gupta SK, Pittenger AL, Swan SK, et al.(2002): Single-dose pharmacokinetics and safety of pegylated interferon alpha2b in patients with chronic renal dysfunction. *J Clin Pharmacol* ;42:1109-1115.

Haber MM, West AB, Haber, AD, Reuben A. (1995): Relationship of aminotransferases to liver histological status in chronic hepatitis C. *Am J Gastroenterol*; 90:1250.

Haberstroh A, Schnober EK, Zeisel MB, Carolla P, et al. (2008): Neutralizing host responses in hepatitis C virus infection target viral entry at post binding steps and membrane fusion. *Gastroenterology*, 135:1719.

Habib M, Mohammed MK, Abd El Hamid M, et al., (2003): Hepatitis C Virus (HCV) infection in a community in the Nile delta: population description And HCV prevalence. *Hepatology* 32 (1) :111-5.

Hadziyannis SJ, SetteHJr, Morgan TR, et al. (2004): Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med*;140:346-355.

Hagan H, Des Jarlais D, Stern R, et al.(2007): HCV Synthesis Project: Preliminary analysis of HCV prevalence in relation to age and duration of infection.*Int J Drug Policy* . 2007 October;18(5): 338-340.

Haley RW and Fischer RP. (2001): Commercial tattooing as a potentially important source of hepatitis C infection. Clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status. *Medicine (Baltimore)*;80:134.

Halfon P, Imbert-Bismut F, Messous D, et al. (2002): A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. *Hepatology*; 1:3.

Harbin WP, Robert NJ, Ferrucci JT Jr. (1980): Diagnosis of cirrhosis based on regional changes in hepatic morphology: a radiological and pathological analysis. *Radiology*; 135:273-278.

Harris DR, Gonin R, Alter HJ, et al. (2001):The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. *Ann Intern Med*;134:120-124.

Herzer K (2007): Hepatitis viruses: live and let die. *Liver Int*; 27(3):293-301.

Hibbs RG, Corwin AL, and Hassan NF (1993): Epidemiology of antibodies to hepatitis C in Egypt. *Journal of Infectious Diseases*; 168: 789-790.

Hilsabeck RC, Perry W, Hassanein TI. (2002): Neuropsychological impairment in patients with chronic hepatitis C. *Hepatology*; 35:440.

Hinrichsen H, Leimenstoll G, Stegen G, et al., (2002):Prevalence and risk factors of hepatitis C virus infection in hemodialysis patients: a multicenter study in 2796 patients. *Gut.*; 51: 429-33.

Hofgartner WT, Kant JA, Weck KE. (2000): Hepatitis C virus quantitation: Optimization of strategies for detecting low-level viremia. *J ClinMicrobiol*;38:888.

Hofmann WP and Zeuzem S (2011):A new standard of care for the treatment of chronic HCV infection. *Nat Rev Gastroenterol Hepatol*May; 8:257.

Hoofnagle JH. (1997): Hepatitis C: the clinical spectrum of disease. *Hepatology*; 26(supplement 1):15S-20S.

Horan TC, Emori, T.G., (1997): Definitions of the key terms used in the NNIS System. *Am J Infect Control* 25: 112-6.

Houghton M, Weiner A, Han J, Kuo G; Choo QL. (1991): Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease. *Hepatology*; 14:381.

Houghton M, Fields BN, Knipe DM, et al., (1996):Hepatitis C viruses. Eds. *Fields Virology*, 3rd ed Philadelphia, Lippincott- Raven: 1035-1058.

Hourigan LF, Macdonald GA, Purdie D, et al. (1999): Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. *Hepatology* ;29:1215-1219.

Hsu HH, Wright TL, Luba D, et al.(1991): Failure to detect HCV genome in human secretion with the PCR.*Hepatology*,14:763-767.

([http://hepatitis.about.com/od/questions/f/Virus live.htm](http://hepatitis.about.com/od/questions/f/Virus_live.htm)).

(<http://investors.vrtx.com/releasedetail.cfm?ReleaseID=505239>) .

65% of people whose prior treatment for hepatitis C was unsuccessful achieved SVR (viral cure) with telaprevir-based therapy in phase 3 REALIZE study [press release]. Cambridge, MA. Vertex; Sep 7 , 2010.

(http://pi.vrtx.com/files/uspi_telaprevir.pdf) Telaprevir (Incivek) capsules [prescribing information]. Cambridge, MA: Vertex; 2011.

(<http://www.businessweek.com/ap/financialnews/D9I3C10G0.htm>).

(http://www.hcvadvocate.org/news/reports/EASL_2009/Advocate_EASL_29_Coverage.htm).

(http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf)

Victrelis (boceprevir) capsules [prescribing information]. Whitehouse Station, NJ: Merck; 2011.

(<http://www.newswise.com/articles/>).

(<http://www.reuters.com/article/idUSTOE69D04U20101014>).

(http://www.wrongdiagnosis.com/h/hepatitis_c/prcvent.htm). Prevention of hepatitis C:

Huang H, Sun F, Owen DM, et al. (2007); Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. *Proc Natl Acad Sci U S A.* 104(14):5848–5853.

Huang Z, Peng J, Cai Z, Huang C, Murray MG. (2010): Novel molecular as a potent HCV helicase inhibitor. 15th International Symposium on Hepatitis C Virus and Related Viruses; San Antonio, TX; Abstract # 278:156.

Hui JM, Sud A, Farrell GC, Bandara P, et al. (2003): Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. *Gastroenterology*;125 :1695- 1704.

Imazeki F, Yokosuka O, Fukai K,(2008): Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus- infected and hepatitis C virus-cleared patients. *Liver international*; 28: 355-362.

Imbert-Bismut F, Ratziu V, Pieroni L, et al.(2001):Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. *Lancet*; 357: 1069-75.

Institute of Medicine of the National Academies.(2006):Preventing HIV infection among Injecting Drug Users in High-Risk Countries: *An Assessment of the Evidence.* Washington, DC: The National Academies Press.

Ippolito G, Puro V, Petrosillo N, et al. (1998): Simultaneous infection with HIV and HCV following occupational conjunctival blood exposure.*JAMA*, 280 : 28.

Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, et al. (1995): Histological grading and staging of chronic hepatitis. *J Hepatol*;22: 696-699.

Ishii K, Rosa O, Watanabe Y, Katayama T, Harada H, et al. (1998): High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. *Hepatology*; 28: 1117.

Ismail AM, Ziada HN, Sheashaa HA, Shehab El-Din AB, (2009): Decline of viral hepatitis prevalence among asymptomatic Egyptian blood donors: A glimmer of hope. *Eur J Intern Med* 20:490–493.

Jacobson IM, Brown RS Jr, Freilich B, et al.(2007): Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. *Hepatology*;46: 971-981.

Jacobson IM et al(2010):Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naïve patients: Final results of phase 3 ADVANCE study. *Hepatology* Oct; 52(S1):427A.

Jaeckel E, Cornberg M, Wedemeyer H, et al. (2001): Treatment of acute hepatitis C with interferon alfa-2b. *N Engl J Med*;345:1452-1457.

Jagger J, Hunt EH, Brand-Elnaggar J, Pearson RD. (1988): Rates of needle-stick injury caused by various devices in a university hospital. *N Engl J Med*, 319:284.

Janjua NZ, Hutin YJ, Akhtar S, Ahmad K ,(2006): Population beliefs about the efficacy of injections in Pakistan's Sindh province. *Public Health* 120:824–833.

Jensen DM, Morgan TR, Marcellin P, et al. (2006): Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. *Hepatology*;43:954-960.

Jeong SH, Qiao M, Nascimbeni M,et al. (2004): Immunization with HCV -like, particles induces humoral and cellular immune responses in nonhuman primates. *J,Viol*, 78: 6995- 3.

Jinushi M (2004): Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. *J Immunol*; 15;173(10):6072-81.

Kabbash IA, et al. (2007): Risk perception and precautions taken by health care workers for HIV infection in haemodialysis units in Egypt. *East Mediterr Health J* 13:392–407.

Kamal SM, El Kamary SS, Shardell MD, et al. (2007):Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. *Hepatology*;46:1732-1740.

Kamel MA,et al.(1994): The epidemiology of *Schistosoma mansoni*, hepatitis B and hepatitis C infection in Egypt. *Ann Trop Med Parasitol* 88:501–509.

Kamili S, Krawczynski K, McCaustland K, Li X, Alter MJ. (2007): Infectivity of hepatitis C virus in plasma after drying and storing at room temperature. *Infect Control Hosp Epidemiol*; 28:519.

Kamimoto Y, Horiuchi S, Tanase S, et al. (1985): Plasma clearance of intravenously injected aspartate aminotransferase isozymes: evidence for referential uptake by sinusoidal liver cells. *Hepatology*; 5: 367-75.

Kaplan M, Gawrieh S, Cotler SJ, Jensen OM. (2003): Neutralizing antibodies in hepatitis C virus infection: a review of immunological and clinical characteristics: *Gastroenterology*; 125:597.

Katsoulidou A, Paraskevis D, Kalapothaki V, et al.(1999):Molecular epidemiology of a HCV outbreak in a haemodialysis unit: Multicentre Haemodialysis Cohort Study on Viral hepatitis. *Nephrol Dial TranspLant*, 14 : 1188-94.

Kaul A, Stauffer S, Berger C, et al. (2009); Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. *PLoS Pathog*. 5(8): 341-354.

Kawaguchi T, Ide T, Taniguchi E, et al. (2007): Clearance of HCV improves insulin resistance, β -cell function, and hepatic expression of insulin receptor substrates 1 and 2. *Am J Gastroenterol*;102: 1-7.

Kelleher TB, Afdhal N. (2005): Noninvasive Assessment of Liver Fibrosis. *Clinics in Liver Disease*; 9: 667-683.

Kennedy M, O'Reilly D, Mah MW.(1998): The use of a quality-improvement approach to reduce needle stick injuries in a Saudi Arabian hospital. *Clin Perform Qual Health Care* 6:79–83.

Khawaja ZA, Gibney L, Ahmed AJ, Vermund SH. (1997): HIV/AIDS and its risk factors in Pakistan. *AIDS* 11:843–848.

Khuroo MS, Khuroo MS, Dahab ST, et al. (2004): Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. *Aliment Pharmacol Ther*;20:931-938.

Kidney disease: improving global outcomes (KDIGO). (2008): *Kidney Int Suppl* :S1-S99.

Kim H, GrossJB, John JR, et al. (2001): Outcome of hospital care of liver disease associated with hepatitis C in the united states. *Hepatology*, 33 :201-6.

Kim . WR., (2002):Global epidemiology and burden of hepatitis C. *Microbes And Infection*. 4:1219-1225.

Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, et al.(1990): Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. *Hepatology* ; 12:671.

Klein RS et al., (1991): Occupational risk for hepatitis C virus infection among NewYork City dentists. *Lancet*; 338: 1539-1542.

Kleiner DE. (2005): The liver biopsy in chronic hepatitis C: a view from the other side of the microscope. *Semin Liver Dis*;25:52-64.

Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A.(2000): Increased risk of diabetes in noncirrhotic patients with chronic hepatitis C virus infection. *Mayo Clin Proc*;75: 355-359.

Kobayashi S, Takeda T, Enomoto M, et al. (2007): Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. *Liver Int*; 27:186-191.

Koff RS, Dienstag JL. (1995): Extrahepatic manifestations of hepatitis C and the association with alcoholic liver disease. *Semin Liver Dis*; 15:101.

Koretz RL, Brezina M, Polito Al, et al., (1993):Non- A, non-B Post transfusion hepatitis: comparing C and non-C hepatitis. *Hepatology*.; 17:361.

Kramer L, Bauer E, Funk G, Hofer H, et al. (2002): Subclinical impairment of brain function in chronic hepatitis C infection. *J Hepatol*; 37:349.

Kramer TH, Gaar GG, Ray CG, et al.(1990):Hemodialysis clearance of intravenously administered ribavirin. *Antimicrob Agents Chemother*;34:489-490.

Krawczyk M, Wasowska-Lukawska M, Oszczapowicz I, (2009); Amidinoanthracyclines – a new group of potential anti-hepatitis C virus compounds. *Biol Chem.* 390(4): 351–360.

Kuo G, Choo QL, Alter HJ, et al., (1989):An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. *Science*; 244: 362-364:

Kuroki T, Nishiguchi S, Fukuda K, Ikeoka N, et al. (1993): Vertical transmission of hepatitis C virus (HCV) detected by HCV-RNA analysis. *Gut*; 34:S52.

Kwok S, Higuchi R. (1989): Avoiding false positives with PCR. *Nature*; 339:237.

Lakkana Thaikruea, Satawat Thongsawat, Niwat Maneekarn, et al.(2004): Risk factors for hepatitis C virus infection among blood donors in Northern Thailand; *TRANSFUSION*; 44: 1433-1440.

Lam JP, McOmish F, Bums SM, et al., (1993): Infrequent vertical transmission of HCV. *J Infect Dis*, 167:572-6.

Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al (2010): Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. *Science*. 327(5962):198–201.

Lau, JYN, Davis, GL, Orito, E, Qian KP, Mizokami M. (1993): Significance of antibody to the host cellular gene derived epitope GOR in chronic hepatitis C virus infection. *J Hepatol*; 17:253.

Lau JYN, Davis GL and Kniffen J (1993):Significance of serum hepatitis C RNA level in chronic HCV infection. *Lancet*; 341: 1501.

Lau JY, Davis GL, Prescott LE, Maertens G, et al. (1996): Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen in tertiary referral centers in the United States. *Ann Intern Med*; 124:868.

Lau JYN, Standring DN. (2000): Development of novel therapies for hepatitis C.In: Liang TJ, Hoofnagle JH, eds. Hepatitis C: Biomedical Research Reports. 1st ed. London, *Academic Press*,;453-467.

Lau JY, Lin CC. (2001): Assessment of liver delivery of ribavirin and viramidine, a liver-targeting ribavirin prodrug, using whole body autoradiography. *Hepatology*;34(Suppl.):427A.

Lau JY, Tam RC, Liang TJ, Hong Z. (2002): Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. *Hepatology*; 35:1002-1009.

Lauer GM and Walker BD, (2001): HCV infection. *N Engl j Med*; 345: 41-52.

Lavanchy D and McMahon B, (2000): Worldwide prevalence and prevention of hepatitis C. In: Liang TJ, Hoofnagle JH, eds. *Hepatitis C. San Diego, Academic Press*, 185-202.

Liang TJ, Rehermann B, Seeft LB, Hoofnagle JH. (2000): Pathogenesis, natural history, treatment, and prevention of hepatitis C. *Ann Intern Med*; 132:296.

Liaw YF. (1995): Role of hepatitis C virus in dual and triple hepatitis virus infection. *Hepatology*; 22:1101.

Lin CC, Luu K, Lourenco D, et al. (2001): Viramidine, a prodrug of ribavirin, demonstrated superior liver-targeting properties and much improved toxicity profile in cynomolgus monkey studies. *Hepatology*;34(Suppl.):453A.

Lindenbach BD, Rice CM. (2005); Unravelling hepatitis C virus replication from genome to function. *Nature*. 436(7053):933–938.

Lissen E, Alter HJ, Abad MA, Torres Y, et al. (1993): Hepatitis C virus infection among sexually promiscuous groups and the heterosexual partners of hepatitis C virus infected index cases. *Eur J Clin Microbiol Infect Dis*; 12:827.

Lok AS, Chien D, Choo QL, Chan TM, Chiu EK, et al. (1993): Antibody response to core, envelope and nonstructural hepatitis C virus antigens: omparison of immunocompetent and immunosuppressed patients. *Hepatology*, 18:497.

Lorvick J, Kral AH, Seal K, et al., (2001): Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. *Am J Public Health* ;91 :46-47.

Lurie Y, Pakula R, Malnick S, et al. (2001): Efficacy and safety of the combination of histamine dihydrochloride and interferon alpha-2b in a phase II

trial in naive patients with chronic hepatitis C [Abstract]. *Hepatology*; 34(Suppl.):350A.

Macdonald A, Harris M. (2004); Hepatitis C virus NS5A: tales of a promiscuous protein. *J Gen Virol.* 85(Pt 9):2485–2502.

Maher L, Jiong L, Jalaludin B, et al., (2007): High hepatitis C incidence in new injecting drug users: a policy failure? *Australian and New Zealand Journal Of Public Health*; 31 (1):30-35. [PubMed: 17333606].

Major ME, Feinstone SM. (1997): The molecular virology of hepatitis C. *Hepatology*; 25 (6): 1527-38.

Makris BA, Garson CJA and Ring PW (2001): Hepatitis C viral RNA in Clotting factor concentrates and the development of hepatitis in recipients. *Blood*; 81: 1898-1902.

Manns MP, McHutchison JG, Gordon SC, et al. (2001): Peginterferon alfa- 2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet*;358:958-965.

Manzini P, Saracco G, Cerchier A, Riva C, et al. (1995): Human immunodeficiency virus infection as risk factor for mother-to-child hepatitis C virus transmission; persistence of anti-hepatitis C virus in children is associated with the mother's anti-hepatitis C virus immunoblotting pattern. *Hepatology*; 21:328.

Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B, et al. (1996):Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. *Clinical Endocrinology*;44: 635-642.

Marcellin P (1999): Hepatitis C , the clinical spectrum of the disease. *J. Hepatol.*31(suppl1.1):9-111.

Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C; et al. (1995): Pre-treatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. *Hepatology*; 22:1050.

Mast EE and Alter MJ (1997). Hepatitis C.*Semin Pediatr Infect Dis* ; 8:17-22.

Mast EE, Alter MJ, Margolis HS (1999): Strategies to prevent and control hepatitis B, and C virus infections: a global perspective. *Vaccine*; 17:1730-1733.

Mastromatteo AM, Rapaccini GL, Pompili M, et al., (2001): HCV infection other biological fluids than blood may be responsible for intrafamilial spread. *Hepato-gastroenterol*; 48: 193-6.

Matsubara T, Sumazaki R, Takita H. (1995); Mother to infant transmission of hepatitis C virus: a prospective study. *Eur J Pediatr*; 154:973.

Matsuo K, Kusano A, Sugumar A, et al. (2004): Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. *Cancer Sci*; 95:745-752.

Mazza C, Ravaggi A, Rodella A, Padula O, Ouse M, Lomini M, et al. (1998): Prospective study of mother to infant transmission of hepatitis C virus (HCV) infection. Study Group for Vertical Transmission. *J Med Virol*; 54:12.

McCormick SE, Goodman ZD, Maydonovitch CL. (1996): Evaluation of liver histology, ALT elevation and HCV RNA titre in patients with chronic hepatitis C. *Am J Gastroenterol*; 91:1516.

McHutchison JG, Blatt LM, de Medina M, et al. (2000): Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. *J Gastroenterol Hepatol*; 15: 945-51.

McHutchison JG, Cheung R, Shiffman ML, et al. (2001): A 4-week trial of VX 497 (an IMPDH inhibitor) combined with interferon in previously untreated patients with chronic hepatitis C [Abstract]. *Hepatology*; 34(Suppl.):329A.

Mehta SH, Cox A, Hoover DR, et al., (2002): Protection against persistence of hepatitis C. *Lancet*, 359: 1478- 83.

Mehta SH, Brancati FL, Strathdee SA, Pankow JS, et al. (2003): Hepatitis C virus infection and incident type 2 diabetes. *Hepatology*; 38: 50-56.

Mele A, Pulsoni A, Bianco E, et al. (2003): Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. *Blood*; 102: 996-9.

Mellor J, Holmes EC, Jarvis LM. (2001):Investigation of the pattern of Hepatitis C virus sequence diversity in different geographical regions: implications for virus classification. *Gen Virol*; 76: 2493-507.

Mendenhall CL, Moritz T, Rouster S, Roselle G, Polito A, Quan S, et al. (1993): Epidemiology of hepatitis C among veterans with alcoholic liver disease. The VA Cooperative Study Group 275. *Am J Gastroenterol*; 88:1022

Merican I, Sherlock S, McIntyre N, Dusheiko GM. (1993): Clinical, biochemical and histological features in 102 patients with chronic hepatitis C virus infection. *Q J Med*; 86: 119.

Meuleman P, Hesselgesser J, Paulson M, et al. (2008); Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. *Hepatology*. (2008);48(6):1761–1768.

Mira L, Silva M, Manso CF.(1994): Scavenging of reactive oxygen species by silibinin dihemisuccinate. *Biochem Pharmacol* ; 48(4): 753-9.

Mitsui T, Iwano K, Masuko K, Yamazaki C; Okamoto H, Tsuda F et al. (1992): Hepatitis C virus infection in medical personnel after needle stick accident. *Hepatology*; 16:1109.

Moataza H., Samar S., Wael T., et al., (2009):Australian Journal of Basic and Applied Sciences, 3(1): 1-8.

Mohamed Abou-Saleh, Paul Davis, Philip Rice, et al., (2008):The effectiveness of behavioural interventions in the primary prevention of Hepatitis C amongst injecting drug users; *Harm Reduct J*.; 5: 25.

Mohamed M, Abdel-Aziz F, Habib M, et al.(1998): Epidemic HCV infection in the Nile Delta (abstractP322). *Presented at the International Meeting on HCV and Related Viruses (Venice, Italy), 1998.*

Mohamed MK. (2004): Epidemiology of HCV in Egypt 2004. *The Afro-Arab Liver Journal*.; 3(2):41-52.

MOHP: <http://shbabmisr.com/print.asp?EgyxpID=17849>

Mok J, Pembrey L, Tovo PA, Newell ML.(2005); European Paediatric Hepatitis C Virus Network. When does mother to child transmission of hepatitis C virus occur? *Arch Dis Child Fetal Neonatal Ed.* Mar;90(2):F156-60.

Montalto G, Soresi M, Aragona F, et al. (1996): Procollagen III and laminin in chronic viral hepatopathies. *Presse Med*; 25: 59-62.

Montgomery SA, Asberg M. (1979): A new depression scale designed to be sensitive to change. *Br J Psychiatry*;134:382-389.

Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, et al. (1998): The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. *Nat Med* ; 4:106

Muerhoff AS, Leary TP, Simons IN, et al.,(1995):Genomic organization of GB viruses A and B :two members of the flaviviridae associated with GB agent hepatitis. *J virol*,69: 5621-30.

Mujeeb SA (1993): Blood transfusion a potential source of HIV/AIDS spread. *J Pak Med Assoc* 43:1.

Myles DC. (2001): Recent advances in the discovery of small molecule therapies for HCV. *Curr Opin Drug Discov Devel*; 4:411-416.

Nafeh MA, Medhat A, Shehata M, Mikhail NN, Abdel-Hamid M,et al. (2000): Hepatitis C in a community in Upper Egypt: I. Cross-sectional survey. *Am. J. Trop. Med. Hyg.*63(5-6):236-41.

Nagao Y, Sata M, Tanikawa K, Itoh K, Kameyama T. (1995): Lichen planus and hepatitis C virus in the northern Kyushu region of Japan. *Eur J Clin Invest*; 25: 910-914.

Naglaa Arafa, Mostafa El Hoseiny, Claire Rekacewicz, et al.(2005): Changing pattern of hepatitis C virus spread in rural areas of Egypt; *J Hepatology*; 43: 418-424.

Nalpas B, Vassault A, Le Guillou A, et al.(1984):Serum activity of mitochondrial aspartate aminotransferase: a sensitive marker of alcoholism with or without alcoholic hepatitis. *Hepatology*; 4: 893-6.

Nalpas B, Driss F, Pol S, Hamelin B, Housset C et al. (1991): Association between HCV and HBV infection in hepatocellular carcinoma and alcoholic liver disease. *J Hepatol*; 12:70.

Naoumov NV, Petrova EP, Thomas MG, et al, (1998): Presence of a newly describe, human DNA virus (TTV) in patients with liver disease. *Lancet*, 352: 197.

National Institutes of Health. (2002): NIH Consensus Development Conference Statement: Management of Hepatitis C 2002: A Preliminary Draft Statement, June 10-12, 2002. Bethesda, Maryland: NIH Consensus Development Program.

Nelson D, Soldevila-Pico C, Abdelmalek M, et al. (2001): Long-term use of recombinant interleukin 10 (IL-10) in patients with advanced chronic hepatitis C: insight into immunopathogenesis [Abstract]. *Hepatology*; 34(Suppl.):430A.

Nguyen MH, Trinh HN, Garcia R, et al, (2008): Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 week versus 24 weeks of peginterferon plus ribavirin. *Am J Gastroenterol*; 103:1131-1135.

Nguyen T, Sedghi-Vaziri A, Wilkes L, Mondala T, Pockros PJ, et al. (1996): Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HGV infection. *J Viral Hepat*; 3:75.

Noda K, Yoshihara H, Suzuki K, et al. (1996): Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma, its relationship to alcohol drinking and the age of transfusion. *Alcohol Clin Exp Res*; 20:95A–100A.

Nomura H, Tanimoto H, Kajiwarra E, et al. (2004): Factors contributing to ribavirin- induced anemia. *J Gastroenterol Hepatol*; 19(11):1312-7.

Ohki T, Tateishi R, Sato T, Masuzaki R, Imamura J, Goto T, et al. (2008): Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. *Clin Gastroenterol Hepatol*; 6:459.

Ohto H, Terazawa S, Sasaki N, Hino K, Ishiwata C, et al. (1994): Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. *N Engl J Med* 1994; 330:744.

Okazaki T, Yoshihara H, Suzuki K, Yamada Y; et al. (1994): Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. *Scand J Gastroenterol*; 29:1039.

Okuda M, Li K, Beard MR, et al. (2002): Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. *Gastroenterology*; 122: 366-75.

Olynyk JK, Reddy KR, Di Bisceglie AM, Jeffers LJ, et al. (1995) : Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. *Gastroenterology*; 108:1104- 1109.

Opar A. (2010); Excitement grows for potential revolution in hepatitis C virus treatment. *Nat Rev Drug Discov*. 9(7):501–503.

Ortiz V, Berenguer M, Rayon JM, et al. (2002): Contribution of obesity to hepatitis C-related fibrosis progression. *Am J Gastroenterol* ;97:2408-2414.

Ortiz-Movilla N, Lazaro P, Rodriguez-Inigo E, et al. (2002): HCV replicates in sweat glands and is released into sweat in patients with CHC. *J Med Virol*, 68 :529-36.

Oshita M, Hayashi N, KaSahara A, et al. (1993): Prevalence of HCV in family members of patients with hepatitis C. *J Med Viral*, 41: 251-5.

Paccagnini, S, Principi, N, Massironi E, Tanzi E, Romano L, et al. (1995): Perinatal transmission and manifestation of hepatitis C virus infection in a high risk population. *Pediatr Infect Dis J*; 14:195.

Paeshuyse J, Kaul A, de Clercq E, et al. (2006): The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. *Hepatology*.;43(4):761–770.

Pares A, Barrera JM, Caballeria J, Ercilla G, Bruguera M, et al. (1990): Hepatitis C virus antibodies in chronic alcoholic patients: Association with severity of liver injury. *Hepatology*; 12:1295.

Park GJ, Lin BP, Ngu MC, et al. (2000): Aspartate aminotransferase: Alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? *J Gastroenterol Hepatol*; 15: 386-90.

Parker J, Parker G, Jagger J. (2004): percutaneous injury rates. *International Healthcare Worker Safety Center, August 2007*; 1.

Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, et al.(2004) : The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. *J Hepatol*;40: 84-490.

Pawlotsky J.M (2004): Pathophysiology of hepatitis C infection and related liver disease. *Trends Microbiol*; 12(2):96-1 02.

Pawlotsky JM (2010); More sensitive hepatitis C virus RNA detection: what for? *J Hepatol*. 52(6):783–785.

Pawlotsky JM (2011): The results of phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: A new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. *Gastroenterol Mar*; 140:746.

Pearlman BL, Ehleben C, Saiffee S. (2007):Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. *Hepatology*;46:1688-1694.

Pedro Mateu, Carla Treloar, Victor Agullo, et al, (2007): How can hepatitis C be preveted in the long term?; *Int J Drug Policy*.2007 October; 18(5): 338-340.

Pereira BJ, Milford EL, Kirkman RL, Quan S, et al. (1992): Prevalence of HCV RNA in hepatitis C antibody positive cadaver organ donors and their recipients. *N Engl J Med*; 327:910.

Pereiera LM, Medo MC, Saleh MG,et al.(1995): HCV infection in Schistosomiasis mansoni in Brazil. *J Med Virol*,45 :423-8.

Pereira BJ, Levey AS. (1997): Hepatitis C virus infection in dialysis and renal transplantation. *Kidney In*; 51:981.

Pereira BJ, Milford EL, Kirkman RL, Levey AS. (1997): Transmission of hepatitis C virus by orgar transplantation. *N Engl J Med*; 325:454.

-
- Perry W, Hilsabeck RC, Hassanein TI. (2008):** Cognitive dysfunction in chronic hepatitis C: a review. *Dig Dis Sci*;53: 307-321.
- Pessione F, Degos F, Marcellin P, et al. (1998):** Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. *Hepatology* ;27:1717-1722.
- Plöckinger U, Krüger D, Bergk A, Weich V, et al. (2007):**Hepatitis C patients have a reduced growth hormone (GH) secretion which improves during long-term therapy with pegylated interferon-a. *Am J Gastroenterol*;102: 2724-2731.
- Pockros PJ. (2002):** Developments in treatment of chronic hepatitis C. *Expert Opin Invest Drugs*;11:1-14.
- Podzorski RP. (2002):** Molecular testing in the diagnosis and management of hepatitis c virus infection. *Arch Pathol Lab Med*; 126:285.
- Poordad F et al; (2011):**for the SPRINT-2 investigators. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med* Mar 31; 364:1195.
- Poynard T, Bedossa P, Opolon P. (1997):**Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. *Lancet*;349:825-832.
- Poynard T, McHutchison J, Manns M, et al. (2003):**Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa2-b and ribavirin. *Hepatology*; 38: 481-92.
- Poynard T, Imbert-Bismut F, Munteanu M, et al. (2004):** Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV Fibrosure) and necrosis (ActiTest) in patients with chronic hepatitis C. *Comp Hepatol*; 3; 8.
- Poynard T, Ratziu V, Naveau S, et al. (2005):**The diagnostic value ofbiomarkers (SteatoTest) for the prediction of liver steatosis.*Comp Hepatol*; 4:10.
- Pradat P, Tillmann HL, Sauleda S, et al. (2007):** Long-term follow up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver- related complications. *J Viral Hepat*;14:556-563.
-

Proust B, Dubois F Bacq Y, et al., (2000): Two successive HCV infections in An IDU. *J Clin Microbiol*, 38: 3125- 27.

Prummel MF, Laurberg P. (2003): Interferon-alpha and autoimmune thyroid disease. *Thyroid*;13: 547-551.

Pruvot FR, Boleslawski E. , Rev Prat. (2009):Mar 20;59(3):304-7.

Puchhammer-Stockl E, Mor W, Kundi M, et al.(1994): Prevalence of HCV RNA in serum and throat washings of children with chronic hepatitis. *J Med Virol*, 43: 143-7.

Qiao M, Murata K, Davis AR, et at, (2003):HCV-like particles combined with novel adjuvant systems enhance virus:specific immune responses. *Hepatology*, 37: 52- 59.

Radloff L. (1977):The CES-D Scale: a self-report depression scale for research in the general population. *J Applied Psychol Measurement*;1:385-401.

Raison CL, Demetrashvili M, Capuron L, et al. (2005): Neuropsychiatric adverse effects of interferon-alpha: recognition and management. *CNS Drugs*;19:105-123.

Rani A.Desai, Robert A.Rosenheck and Vincent Agnello(2003): Prevalence of hepatitis C virus infection in a sample of homeless veterans; *Soc Psychiatry Epidemiology*; 38: 396-401.

Reeves HL, Friedman SL. (2002): Activation of hepatic stellate cells: a key issue in liver fibrosis. *Front Biosci*;7:808-826.

Reiss G, Keeffe EB. 2005):Role of liver biopsy in the management of chronic liver disease: selective rather than routine. *Rev Gastroenterol Disord*:195-205.

Resti M, Azzari C, Mannelli F, et al., (1998:) Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV1. *BMJ*; 317: 437-41.

Robert L, Carithers JR., (1999): Hepatitis C and renal failure. *Am. J. Med.*; 107: 90-4.

Romero-Gomez M, Grande L, Nogales MC, et al.(2001): Intrahepatic hepatitis C virus replication is increased in patients with regular alcohol consumption. *Dig Liver Dis*;33:698-702.

Romero-Gomez M, Del Mar Vilorio M, Andrade RJ, et al. (2005): Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. *Gastroenterology*;128:636-641.

Romero-Lopez C, Diaz-Gonzalez R, Barroso-delJesus A, (2009); Inhibition of hepatitis C virus replication and internal ribosome entry site-dependent translation by an RNA molecule. *J Gen Virol.* 90(Pt 7):1659–1669.

Rossi G, Tucci A, Cariani E, et al .(2003):Outbreak of HCV infection in patients with hematologic disorders treated with IV immunoglobulins : different prognosis according to the immune status. *Blood*, 90 : 1309-4.

Rossignol JF, Elfert A, Keeffe EB(2010): Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide. *J Clin Gastroenterol.* 44(7):504–509.

Rostaing L, Chatelut E, Payen JL, et al.(1998): Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. *J Am Soc Nephrol*;9:2344-2348.

Saadoun D, Asselah T, Resche-Rigon M, et al. (2006): Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C. *Hepatology*; 43: 1337-1345.

Sanchez-Fueyo A, Restrepo JC, Quinto L, et al. (2002): Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. *Transplantation*;73:56-63.

Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. 2003):Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. *Ultrasound Med Biol*, 9:1705-1713.

Sangnelli E, Coppola N, Messina V, et al., (2002): HBV superinfection in HCV chronic carriers, viral interaction and clinical course. *Hepatology*, 36: 1285-91.

Scheuer PJ. (1991) : Classification of chronic viral hepatitis: a need for reassessment. *J Hepatol*;13:372-374.

Schinazi RF, Bassit L, Gavegnano C. (2010): HCV drug discovery aimed at viral eradication. *J Viral Hepat.*;17(2):77–90.

Schneeberger PM, Keur I, Van Loon AM ,et al. (2000): The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a national prospective study. *J. Infect. Dis.*; 182: 1291-302.

Schoeman MN, Liddle C and Bilous M (1990): Chronic non-A, non-B hepatitis: lack of correlation between biochemical and morphological activity, and effects of immunosuppressive therapy on disease progression. *Aust NZ J Med*; 20:56-62.

Seeff LB, Hollinger B, Alter HJ, Wright EC, Cain CM, et al. (2001): Long term mortality and morbidity of transfusion associated non-A, non-B and type C hepatitis: a National Heart, Lung and Blood Institute collaborative study. *Hepatology*; 33(2):455-63.

Seeff, LB. (2002): Natural history of chronic hepatitis C. *Hepatology*; 36:S35.

Shalaby S, Kabbash IA, El Saleet G, Mansour N, Omar A ,et al. (2010): Hepatitis Band C viral infection: prevalence, knowledge, attitude and practice among barbers and clients in Gharbia governerate, Egypt. *East.Mediterr.Health J*,16(1):10-7.

Sharara AI et al., (1996):Hepatitis C. *Ann Intern Med*; 125: 658-668.

Sherlock S and Dooley J (1997)a: Diseases of the liver and billiary system(10th edition). Sherlock and Dooley, J. (eds.) *Blackwell Scientific Publications USA., Canada, Australia*, pp. 310,311.

Sherman M, Shafran S, Burak K, et al. (2007): Management of chronic hepatitis C: Consensus guidelines. *Can J Gastroenterol.*;21(Suppl C):25C–34C.

Sherman KE et al(2010):Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naïve genotype 1 HCV patients who achieved an extended rapid viral response: Final results of phase 3 ILLUMINATE study. *Hepatology* Oct; 52(S1):401A.

Shiffman ML, Suter F, Bacon BR, et al. (2007): Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype2 or 3.*N Engl J Med*;357:124-134.

Silini E, Locasciulli A, Santoleri L, Gargantini L, et al.(2002):Hepatitis C virus infection in a hematology ward: evidence for nosocomial transmission and impact on hematologic disease outcome. *Haematologica*; 87(11): 1200-8

Simmonds P, Alberti A, Alter HJ, Bonino F, et al. (1994): A proposed system for the nomenclature of hepatitis C viral genotypes (letter). *Hepatology*; 19:1321.

Simmonds P, Bukh J, Combet C, et al. (2005): Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. *Hepatology*; 42:962.

Soetjipto M, Handajani R, Lusida ML ,et al., (1996): Differential prevalence of hepatitis C virus subtypes in healthy blood donors, patients on maintenance hemodialysis, and patients with hepatocellular carcinoma in Surabaya, Indonesia. *J. Clin. Microbiol.*; 34: 2875-80.

Soffredini R, Rumi MG, Lampertico P, Aroldi A, et al. (1996): Increased detection of antibody to hepatitis C virus in renal transplant patients by third-generation assays. *Am J Kidney Dis*; 28:437.

Soza A, Everhart JE, Ghany MG, et al. (2002): Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. *Hepatology*;36:1273-1279.

Srinivasan R. (2001):Autoimmune hemolytic anemia in treatment naive chronic hepatitis C infection. *J Clin Gastroenterol*;32: 245–247.

Stölzel U, Köstler E, Koszka C, et al. (1995): Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany. *Hepatology*;21:1500-3.

Strader DB, Wright T, Thomas DL, Seeff LB. (2004): Diagnosis, management, and treatment of hepatitis C. *Hepatology*.;39:1147–71.

Strickland GT. (2006): Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. *Hepatology*; 43(5):915-22.

Strickland GT, El Hefni H, Salman T, et al.(2002):Role of hepatitis C infection in CLD in Egypt. *Am J Trop Med Hyg*, 67 :436-42.

Takahashi M, Yamada G, Miyamoto R.(1993): Natural course of chronic hepatitis C. *AM J. Gastroenterol.*, 88: 240-243.

Takehara K, Otsuka T, Arai T, Matsuzaki Y, et al. (1994): Detection of hepatitis C virus (HCV) in platelets of type C chronic liver diseases by polymerase chain reaction (PCR). *Gastroenterology*;106: A995.

Tan SL, Katze MG. (2001); How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. *Virology.* 284(1):1–12.

Tanaka Y, Agha S, Saady N, Kurbanov F, et al. (2004): Exponential Spread of Hepatitis C Virus Genotype 4a in Egypt. *J Molecular Evolution.*; 58(2):191-5

Tarantola A, Abitebo VID, Rachline A. (2006): Infection risks following accidental exposure to blood or body fluids in health care workers:a review of pathogens transmitted in published cases. *Am J Infect Control*; 34:367

Taylor D.R. (2000): Hepatitis C virus and interferon resistance.*Microbes and Infection*; 2:1743-56.

Teare JP, Sherman D, Greenfield SM, et al. (1993): Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. *Lancet*; 342: 895-8

Terrault NA, Wright TL, Pereira BJ. (1995): Hepatitis C infection in the transplant recipients. *Infect. Dis. Clin. North Am.*; 9: 943-64.

Thomas SL, Newell ML, Peckham CS, et al., (1998):A review of hepatitis C virus (HCV) vertical transmission: risk of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. *Int J Epidemiol*;27: 1 08-17.

Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC. (1999): Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. *Lancet*; 354:2119.

Tobler LH, Lee SR, Stramer SL Peterson J, et al. (2000): Performance of second- and third-generation RIBAs for confirmation of third generation HCV EIA-reactive blood donations. Retrovirus Epidemiology Donor Study. *Transfusion*; 40:917.

Tobler LH, Stramer SL, Lee SR, Masecar BL, et al. (2003): Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood-donor screening. *Transfusion*; 43: 1452.

Tong MJ, EI-Farra NS, Reikes AR, (1995): Clinical outcomes after transfusion-associated hepatitis C. *N Engl J Med*; 332: 1463.

Trinchet JC, Hartmann DJ, Pateron D, et al. (1991): Serum type I collagen and N terminal peptide of type III procollagen in chronic hepatitis. Relationship to liver histology and conventional liver tests. *J Hepatol*; 12: 139-44.

Uchihara M, Izumi N, Sakai Y, et al. (1998): Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon. *Nephron*;80:51-56.

Ueda T, Ohta K, Suzuki N, Yamaguchi M, Hirai K, et al. (1992): Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. *Am Rev respire Dis*;146: 266-268.

Vallet S, Gouriou S, Nousbaum JB, Legrand-Quillien MC, Goudeau A, (2005); Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients. *J Med Virol*. 75(4):528–537.

Van Damme P et al., (1998): Epidemiology of hepatitis B and C in Europe. *Acta Gastroenterologica Belgica*; 61:] 75- 182.

Veldt BJ, Heathcote EJ, Wedemeyer H, et al. (2007): Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. *Ann Intern Med* ;147:677-684.

Vezali E, Elefsiniotis I, Mihas C, Konstantinou E, Saroglou G. (2009): Thyroid dysfunction in patients with chronic hepatitis C: Virus-or therapy-related? *J Gastroenterol Hepatol*;24: 1024-1029.

Villano SA, Vlahov O, Nelson KE, Cohn S, Thomas DL. (1999): Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. *Hepatology* ;29:908

Vogel W, Graziadei I, Umlauf F, et al. (1996): High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study. *Dig Dis Sci*;41:81S– 85S.

Vrieling H, Reesink HW and Van den Burg PJ N (1997): Performance of three generations of anti-hepatitis C virus enzyme linked immunosorbant assays in donors and patients. *Transfusion*; 37:845-849.

Vrieling H, Van Der Poel, Reesink HW, et al., (1995): Transmission of hepatitis C virus by anti-HCV-negative blood transfusion. Case and report. *Vox Sang*; 68:55-56.

Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, Bourne N, et al. (2010): multiple effects of silymarin on the hepatitis C virus lifecycle. *Hepatology*; 51(6):1912-21.

Wai CT, Greenson JK, Fontana RJ, et al. (2003): A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology*; 38: 518-26.

Waked IA, Saleh SM, Moustafa MS, et al., (1995): High prevalence of hepatitis C in Egyptian patients with chronic liver disease. *Gut*, 37: 105-107.

Wang CS, Yao WJ, Wang ST, Chang TT, Chou P. (2004): Strong association of Hepatitis C virus (HCV) infection and thrombocytopenia: implications from a survey of a community with hyperendemic HCV infection. *Clin Infect Dis*; 39: 790-796.

Watashi K. (2010); Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection. *Curr Opin Investig Drugs*. 11(2):213–224.

Wertheimer A.M (2003): Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. *Hepatology*; 37(3):577-89.

Westin J, Lagging M, Dhillon AP, Norkrans G, Romero AI, Pawlotsky JM, et al. (2007) : Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. *J Viral Hepat*; 14:29-35.

White DL, Ratziu V, El-Serag HB. (2008): Hepatitis C infection and risk of diabetes: A systematic review and metaanalysis. *J Hepatol*; 49: 831-844.

(WHO)World Health Organization. (2002). Hepatitis C fact sheet.Geneva:
<http://www.who.int/mediacentre/factsheets/fs164/en/>

Wiley TE, McCarthy M, Breidi L, et al. (1998): Impact of alcohol on the histological and clinical progression of hepatitis C infection. *Hepatology*; 28:805-809.

Witherell GW. (2001): ISIS-14803 (ISIS Pharmaceuticals).*Curr Opin Invest Drugs*;2:1523-1529.

Wong VS, Egner W, Elsey T, Brown D, Alexander GJ. (1996): Incidence, character and clinical relevance of mixed cryoglobulinaemia in patients with chronic hepatitis C virus infection. *Clin Exp Immunol*;104: 25-31.

Wright J, Chandra Madhavi and Rekha Thippavazzula, (2002): Expanding the infection control team: Development of the Infection Control liaison position for the neonatal intensive care unit. *Am J Infect Control* 30: 174-8

Yazdanpanah, De Carli, B.Migueres, et al.(2005): Risk Factors for Hepatitis C Virus Transmission to Health Care Workers after Occupational Exposure:A European Case-Control Study: Occupational HCV Transmission Risk Factors. *CID* :41(15 November):1423-1430

Yu JW, Wang GQ, Sun LJ, et al. (2007):Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. *J Gastroenterol Hepatol*;22:832-836.

Zafar A, Aslam N, Nasir N, Meraj R, Mehraj V (2008): Knowledge, attitudes and practices of health care workers regarding needle stick injuries at a tertiary care hospital in Pakistan. *J Pak Med Assoc* 58:57–60.

Zampieron A, Jayasekera H, Elseviers M, Lindley E, De Vos JY,et al (2004): European study on epidemiology and the management of HCV in the haemodialysis population-Part 1:centre policy. *EDTNA ERCA J. ; 30(2):84- 90.*

Zanetti AR, Tnzi E, Paccagnimi S, et al.(1995): Mother-to-infant transmission of HCV. *Lancet*,345: 289-90.

Zanetti AR, Tanzi E, Romano L, Zuin G, et al. (1998): A prospective study on mother-to-infant transmission of hepatitis C virus. *Inter virology*; 41:208.

Zarski JP, Mc Hutchison J, Bronowicki JP, Sturm N, et al. (2003): Rate of natural disease progression in patients with chronic hepatitis C. *J Hepatol*; 38:307.

Zeuzem S, Welsch C, Herrmann E. (2003): Pharmacokinetics of peginterferons. *Semin Liver Dis*;23(Suppl 1):23-28.

Zeuzem, S. (2004): Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? *Ann Intern Med*; 140:370.

Zhang X. (2002): Inhibitors of hepatitis C: a review of the recent patent literature. *IDrugs*;5:154-158.

Zung WW. (1965): A Self-Rating Depression Scale. *Arch Gen Psychiatry*; 12:63-70.